Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:22:08 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:BCLI - BRAINSTROM CELL THERAPEUTICS - http://www.brainstorm-cell.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCLI - Q0.10.4573·0.58980.10.5143-0.0265-4.91,079.94939770.5634  0.59  0.45123.373  0.13417:00:08Apr 1615 min RT 2¢

Recent Trades - Last 10 of 977
Time ETExPriceChangeVolume
17:00:08Q0.5033-0.0375459
16:50:21Q0.4886-0.052210
16:27:11Q0.5116-0.029215
16:00:01Q0.5143-0.0265462
16:00:01Q0.5143-0.026557,675
15:59:12Q0.51-0.0308100
15:58:25Q0.51-0.030840
15:58:14Q0.5111-0.02971,500
15:58:04Q0.5266-0.0142800
15:58:04Q0.5266-0.01424,912

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 18:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
2024-04-11 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
2024-04-10 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's(TM) Phase 3 Clinical Trial in ALS
2024-04-09 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
2024-04-08 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Provide Update on NurOwn Program
2024-04-01 08:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
2024-02-27 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn(TM) Trial Design at MDA Clinical and Scientific Conference
2024-02-23 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn(TM) in ALS
2024-02-13 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
2024-01-02 12:04U:BCLINews ReleaseBCLI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - BCLI
2023-12-29 18:34U:BCLINews ReleaseBCLI FINAL DEADLINE ALERT: ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Initiated by the Firm - BCLI
2023-12-27 16:06U:BCLINews ReleaseROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-26 15:03U:BCLINews ReleaseROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-26 07:30U:BCLINews ReleaseBrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
2023-12-25 10:07U:BCLINews ReleaseROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-24 10:06U:BCLINews ReleaseROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-23 09:03U:BCLINews ReleaseROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-22 21:03U:BCLINews ReleaseROSEN, A LONGSTANDING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-20 09:00U:BCLINews ReleaseBrainStorm Issues 2023 Letter to Shareholders
2023-12-17 16:00U:BCLINews ReleaseROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI